Abstract:Xinkai Luo, 1, &ast Ying Wang, 2, &ast Yufei Mao, 3, &ast Xiaowei Xu, 1, 4 Weifeng Gu, 1 Wen Li, 1 Chaoming Mao, 1 Tingting Zheng, 1 Liyang Dong 1 1 Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China; 2 Department of Respiratory Diseases, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, Jiangsu, People's Republic of China; 3 Department of Ultrasound Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China; 4 Department of Laboratory Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Liyang Dong; Tingting Zheng, Email ; Background: Nebulization of hypoxic human umbilical cord mesenchymal stem cell-derived extracellular vesicles (Hypo-EVs) can suppress airway inflammation and remodeling in a chronic asthmatic mouse; however, the exact mechanism remains unclear. Recently, airway epithelial barrier defects have been regarded as crucial therapeutic targets in asthma. The aim of this study was to investigate whether and how Hypo-EVs protect against the disruption of the airway epithelial barrier under asthmatic conditions. Methods: The therapeutic effects of Hypo-EVs on airway epithelial barrier defects were evaluated in ovalbumin (OVA)-induced asthmatic mice and in IL-4 and IL-13-induced HBE135-E6E7 cell models by detecting cell monolayer leakage and junctional protein expression. The protein levels in Hypo-EVs were determined by Western blotting, and a gene knockdown approach was used to investigate the biofactors in Hypo-EVs. Results: Nebulization of Hypo-EVs directly alleviated airway epithelial barrier defects in asthmatic mice, as evidenced by colocalization with bronchial epithelial cells, decreased albumin concentration, and increased ZO-1 and E-cadherin expression. In vitro, Hypo-EV treatment dramatically rescued the increase in airway cell permeability, and upregulated the ZO-1 and E-cadherin protein expressions. Based on WB analysis, we found that caveolin-1 (CAV-1) was strongly enriched in Hypo-EVs. The knockdown of CAV-1 protein levels in Hypo-EVs significantly impaired Hypo-EV-mediated barrier protection in vitro and in vivo. Moreover, CAV-1 knockdown significantly abolished the beneficial effects of Hypo-EVs on airway inflammation and remodeling in asthmatic mice. In addition, we showed that IL-4/IL-13-induced airway epithelial barrier defects were mainly related to activation of STAT6 phosphorylation (p-STAT6), and overexpression of CAV-1 or Hypo-EV treatment inhibited the levels of p-STAT6 in IL-4/IL-13-induced HBE135-E6E7 cells. Conclusion: Nebulization of Hypo-EVs can attenuate airway epithelial barrier defects in asthma by delivering CAV-1 to inhibit p-STAT6 expression and may be used to treat other barrier defect diseases. Keywords: nebulization, Hypo-EVs, asthma, airway epithelial barrier, caveolin-1 Asthma is a common chronic respiratory disease that affects at least 300 million people worldwide. 1 It is characterized by airway inflammation and remodeling, which may result in small airway narrowing, exhalation dysfunction and even patient death. 2 Inhaled corticosteroids are the most basic treatment for asthma; they can provisionally control respiratory symptoms but do not focus on disease regression, additionally, their long-term use has certain side effects on general health. 3,4 Therefore, effective and safe therapeutic strategies for asthma are urgently needed. The pathogenesis of asthma has been the subject of intensive study in recent decades, and it is now widely accepted that the disruption of airway epithelial barrier (AEB) represents a key factor in the aetiology of asthma. 5,6 The AEB is constituted by adjacent bronchial epithelial cells, with junctional proteins (such as E-cadherin and ZO-1) attaching to neighbouring cells and controlling paracellular transport. In asthmatic conditions, the AEB function is impaired, as indicated by decreased junctional protein expression and increased epithelial barrier permeability, which enables external allergens to penetrate the airway submucosa, subsequently triggering the type-2 inflammation response. 7 Type-2 immune cytokines, such as interleukin-4 (IL-4) and IL-13 induce a number of processes associated with the development of airway inflammation and remodeling, including eosinophil recruitment, goblet cell hyperplasia, and extracellular ma -Abstract Truncated-

The barrier-protective effect of β-eudesmol against type 2-inflammatory cytokine-induced tight junction disassembly in airway epithelial cells

REV-ERBα agonist SR10067 attenuates Th2 cytokine-mediated barrier dysfunction in human bronchial epithelial cells

Protective effects of inhalation of essential oils from Mentha piperita leaf on tight junctions and inflammation in allergic rhinitis

Effects of cigarette smoke on barrier function and tight junction proteins in the bronchial epithelium: protective role of cathelicidin LL-37

Effects of Phosphodiesterase 4 Inhibitor on Cough Response in Guinea Pigs Sensitized and Challenged with Ovalbumin

1,25-Dihydroxyvitamin D-3 Prevents Toluene Diisocyanate-Induced Airway Epithelial Barrier Disruption

Epimedin C modulates the balance between Th9 cells and Treg cells through negative regulation of noncanonical NF-κB pathway and MAPKs activation to inhibit airway inflammation in the ovalbumin-induced murine asthma model

Maintenance of airway epithelial barrier integrity via the inhibition of AHR/EGFR activation ameliorates chronic obstructive pulmonary disease using effective-component combination

Berberine Inhibits Pro-inflammatory Cytokine-induced IL-6 and CCL11 Production via Modulation of STAT6 Pathway in Human Bronchial Epithelial Cells

Function-specific IL-17A and dexamethasone interactions in primary human airway epithelial cells

Effect of ethyl pyruvate on E-cadherin of airway epithelium in a TDI-induced mouse asthma

Eucalyptol, limonene and pinene enteric capsules attenuate airway inflammation and obstruction in lipopolysaccharide-induced chronic bronchitis rat model via TLR4 signaling inhibition

Barrier dysfunction in the nasal allergy

Il4 And Il-17a Provide A Th2/Th17-Polarized Inflammatory Milieu In Favor Of Tgf-Beta 1 To Induce Bronchial Epithelial-Mesenchymal Transition (Emt)

Interleukin-28B dampens protease-induced lung inflammation via IL-25 and TSLP inhibition in epithelial cells

Eriobotrya japonica leaf extract attenuates airway inflammation in ovalbumin-induced mice model of asthma

ED Formula, a Complex of Ecklonia cava and Chrysanthemum indicum, Ameliorates Airway Inflammation in Lipopolysaccharide-Stimulated RAW Macrophages and Ovalbumin-Induced Asthma Mouse Model

[Effects of Regulatory Peptides on Adhesion of Eosinophil to Bronchial Epithelial Cells].

Phytotherapeutic BS012 and Its Active Component Ameliorate Allergic Asthma via Inhibition of Th2-Mediated Immune Response and Apoptosis

Protective effects of Angelica decursiva Franchet & Savatier on allergic responses through enhancement of Nrf2 and suppression of NF-kB/MMP-9 in ovalbumin-exposed mice

Nebulization of Hypoxic hUCMSC-EVs Attenuates Airway Epithelial Barrier Defects in Chronic Asthma Mice by Transferring CAV-1